Effect of Kami Guibi-tang (KGT) in elderly subjects with insomnia: a study protocol from a single center, randomized, double-blind, placebo-controlled trial

Background The incidence of insomnia increases with age and is related to cognitive function in older adults; therefore, it is important to manage it actively. In this study, we report a protocol for the evaluation of the efficacy and safety of Kami Guibi-tang (KGT), a herbal prescription that has b...

Full description

Saved in:
Bibliographic Details
Published inBMC complementary and alternative medicine Vol. 23; no. 1; p. 375
Main Authors Lee, Kyeong-Hwa, Lee, Han-Gyul, Kwon, Seungwon, Park, Seong-Uk, Jung, Woo-Sang, Moon, Sang-Kwan, Park, Jung-Mi, Ko, Chang-Nam, Cho, Seung-Yeon
Format Journal Article
LanguageEnglish
Published London BioMed Central Ltd 23.10.2023
BioMed Central
BMC
Subjects
Adults
Aged patients
biomedical research
Blood
Bulletin boards
Cardiovascular disease
Clinical medicine
Clinical trials
cognition
Cognition & reasoning
Cognitive ability
cognitive disorders
complement
Consent
Dementia
Depression, Mental
drug therapy
Drugs
East Asia
Effectiveness
elderly
Electrocardiogram
Electrocardiography
Geriatrics
Granular materials
Herbal medicine
Hospitals
Insomnia
Kami Guibi-tang
Medical examination
Medical research
Medicine, Experimental
Mental disorders
Neuropsychology
Older people
Patients
Placebos
Protocol
Psychotropic drugs
Quality of life
Questionnaires
Randomized controlled trial
Safety
Sleep
Sleep deprivation
Sleep disorders
Study Protocol
Subjective cognitive decline
surveys
South Korea
East Asia
Online AccessGet full text

Cover

Abstract Background The incidence of insomnia increases with age and is related to cognitive function in older adults; therefore, it is important to manage it actively. In this study, we report a protocol for the evaluation of the efficacy and safety of Kami Guibi-tang (KGT), a herbal prescription that has been widely used in East Asia for insomnia, forgetfulness, and depression, in older adults with insomnia. Methods In this single-center, double-blind, randomized controlled trial, 60 older adults with insomnia and subjective cognitive decline will be recruited and randomly assigned to the KGT or placebo group. The KGT group will take KGT granules thrice a day for 12 weeks, whereas the control group will take placebo granules in the same manner. Participants will be assessed for sleep, cognitive function, quality of life, and depression using the Pittsburgh Sleep Quality Index-Korean (PSQI-K), Insomnia Severity Index-Korean (ISI-K), Seoul Neuropsychological Screening Battery-Dement (SNSB-D), 36-item MOS Short Form Survey (SF-36) and Short version of the Geriatric Depression Scale (S-GDS) before and at the end of administration of the investigational product. The PSQI-K, ISI-K, and SF-36 will be further assessed 12 weeks after the end of medication to determine whether the effects on sleep and quality of life are sustained. The PSQI-K total score difference between the two groups at 12 and 24 weeks will be the primary outcome; all other endpoints will be secondary. Safety will be assessed by performing blood tests and electrocardiograms before taking the investigational drug, 6 weeks after taking the drug, and 12 weeks after taking the drug; any adverse events will be observed throughout the study. Discussion The protocol will provide a detailed process for a clinical trial to evaluate the efficacy and safety of KGT in elderly patients with insomnia. We will also investigate if changes in cognitive function correlated with improvements in insomnia. Trial registration This trial was registered at CRIS (Clinical Research Information Service) on April 27, 2023 (KCT0008391, version 2.0). Keywords: Insomnia, Subjective cognitive decline, Kami Guibi-tang, Herbal medicine, Randomized controlled trial, Protocol
AbstractList Background The incidence of insomnia increases with age and is related to cognitive function in older adults; therefore, it is important to manage it actively. In this study, we report a protocol for the evaluation of the efficacy and safety of Kami Guibi-tang (KGT), a herbal prescription that has been widely used in East Asia for insomnia, forgetfulness, and depression, in older adults with insomnia. Methods In this single-center, double-blind, randomized controlled trial, 60 older adults with insomnia and subjective cognitive decline will be recruited and randomly assigned to the KGT or placebo group. The KGT group will take KGT granules thrice a day for 12 weeks, whereas the control group will take placebo granules in the same manner. Participants will be assessed for sleep, cognitive function, quality of life, and depression using the Pittsburgh Sleep Quality Index-Korean (PSQI-K), Insomnia Severity Index-Korean (ISI-K), Seoul Neuropsychological Screening Battery-Dement (SNSB-D), 36-item MOS Short Form Survey (SF-36) and Short version of the Geriatric Depression Scale (S-GDS) before and at the end of administration of the investigational product. The PSQI-K, ISI-K, and SF-36 will be further assessed 12 weeks after the end of medication to determine whether the effects on sleep and quality of life are sustained. The PSQI-K total score difference between the two groups at 12 and 24 weeks will be the primary outcome; all other endpoints will be secondary. Safety will be assessed by performing blood tests and electrocardiograms before taking the investigational drug, 6 weeks after taking the drug, and 12 weeks after taking the drug; any adverse events will be observed throughout the study. Discussion The protocol will provide a detailed process for a clinical trial to evaluate the efficacy and safety of KGT in elderly patients with insomnia. We will also investigate if changes in cognitive function correlated with improvements in insomnia. Trial registration This trial was registered at CRIS (Clinical Research Information Service) on April 27, 2023 (KCT0008391, version 2.0). Keywords: Insomnia, Subjective cognitive decline, Kami Guibi-tang, Herbal medicine, Randomized controlled trial, Protocol
The incidence of insomnia increases with age and is related to cognitive function in older adults; therefore, it is important to manage it actively. In this study, we report a protocol for the evaluation of the efficacy and safety of Kami Guibi-tang (KGT), a herbal prescription that has been widely used in East Asia for insomnia, forgetfulness, and depression, in older adults with insomnia. In this single-center, double-blind, randomized controlled trial, 60 older adults with insomnia and subjective cognitive decline will be recruited and randomly assigned to the KGT or placebo group. The KGT group will take KGT granules thrice a day for 12 weeks, whereas the control group will take placebo granules in the same manner. Safety will be assessed by performing blood tests and electrocardiograms before taking the investigational drug, 6 weeks after taking the drug, and 12 weeks after taking the drug; any adverse events will be observed throughout the study. The protocol will provide a detailed process for a clinical trial to evaluate the efficacy and safety of KGT in elderly patients with insomnia. We will also investigate if changes in cognitive function correlated with improvements in insomnia.
The incidence of insomnia increases with age and is related to cognitive function in older adults; therefore, it is important to manage it actively. In this study, we report a protocol for the evaluation of the efficacy and safety of Kami Guibi-tang (KGT), a herbal prescription that has been widely used in East Asia for insomnia, forgetfulness, and depression, in older adults with insomnia.BACKGROUNDThe incidence of insomnia increases with age and is related to cognitive function in older adults; therefore, it is important to manage it actively. In this study, we report a protocol for the evaluation of the efficacy and safety of Kami Guibi-tang (KGT), a herbal prescription that has been widely used in East Asia for insomnia, forgetfulness, and depression, in older adults with insomnia.In this single-center, double-blind, randomized controlled trial, 60 older adults with insomnia and subjective cognitive decline will be recruited and randomly assigned to the KGT or placebo group. The KGT group will take KGT granules thrice a day for 12 weeks, whereas the control group will take placebo granules in the same manner. Participants will be assessed for sleep, cognitive function, quality of life, and depression using the Pittsburgh Sleep Quality Index-Korean (PSQI-K), Insomnia Severity Index-Korean (ISI-K), Seoul Neuropsychological Screening Battery-Dement (SNSB-D), 36-item MOS Short Form Survey (SF-36) and Short version of the Geriatric Depression Scale (S-GDS) before and at the end of administration of the investigational product. The PSQI-K, ISI-K, and SF-36 will be further assessed 12 weeks after the end of medication to determine whether the effects on sleep and quality of life are sustained. The PSQI-K total score difference between the two groups at 12 and 24 weeks will be the primary outcome; all other endpoints will be secondary. Safety will be assessed by performing blood tests and electrocardiograms before taking the investigational drug, 6 weeks after taking the drug, and 12 weeks after taking the drug; any adverse events will be observed throughout the study.METHODSIn this single-center, double-blind, randomized controlled trial, 60 older adults with insomnia and subjective cognitive decline will be recruited and randomly assigned to the KGT or placebo group. The KGT group will take KGT granules thrice a day for 12 weeks, whereas the control group will take placebo granules in the same manner. Participants will be assessed for sleep, cognitive function, quality of life, and depression using the Pittsburgh Sleep Quality Index-Korean (PSQI-K), Insomnia Severity Index-Korean (ISI-K), Seoul Neuropsychological Screening Battery-Dement (SNSB-D), 36-item MOS Short Form Survey (SF-36) and Short version of the Geriatric Depression Scale (S-GDS) before and at the end of administration of the investigational product. The PSQI-K, ISI-K, and SF-36 will be further assessed 12 weeks after the end of medication to determine whether the effects on sleep and quality of life are sustained. The PSQI-K total score difference between the two groups at 12 and 24 weeks will be the primary outcome; all other endpoints will be secondary. Safety will be assessed by performing blood tests and electrocardiograms before taking the investigational drug, 6 weeks after taking the drug, and 12 weeks after taking the drug; any adverse events will be observed throughout the study.The protocol will provide a detailed process for a clinical trial to evaluate the efficacy and safety of KGT in elderly patients with insomnia. We will also investigate if changes in cognitive function correlated with improvements in insomnia.DISCUSSIONThe protocol will provide a detailed process for a clinical trial to evaluate the efficacy and safety of KGT in elderly patients with insomnia. We will also investigate if changes in cognitive function correlated with improvements in insomnia.This trial was registered at CRIS (Clinical Research Information Service) on April 27, 2023 (KCT0008391, version 2.0). https://cris.nih.go.kr/cris/search/detailSearch.do?seq=24811&search_page=L .TRIAL REGISTRATIONThis trial was registered at CRIS (Clinical Research Information Service) on April 27, 2023 (KCT0008391, version 2.0). https://cris.nih.go.kr/cris/search/detailSearch.do?seq=24811&search_page=L .
BackgroundThe incidence of insomnia increases with age and is related to cognitive function in older adults; therefore, it is important to manage it actively. In this study, we report a protocol for the evaluation of the efficacy and safety of Kami Guibi-tang (KGT), a herbal prescription that has been widely used in East Asia for insomnia, forgetfulness, and depression, in older adults with insomnia.MethodsIn this single-center, double-blind, randomized controlled trial, 60 older adults with insomnia and subjective cognitive decline will be recruited and randomly assigned to the KGT or placebo group. The KGT group will take KGT granules thrice a day for 12 weeks, whereas the control group will take placebo granules in the same manner.Participants will be assessed for sleep, cognitive function, quality of life, and depression using the Pittsburgh Sleep Quality Index-Korean (PSQI-K), Insomnia Severity Index-Korean (ISI-K), Seoul Neuropsychological Screening Battery–Dement (SNSB-D), 36-item MOS Short Form Survey (SF-36) and Short version of the Geriatric Depression Scale (S-GDS) before and at the end of administration of the investigational product. The PSQI-K, ISI-K, and SF-36 will be further assessed 12 weeks after the end of medication to determine whether the effects on sleep and quality of life are sustained. The PSQI-K total score difference between the two groups at 12 and 24 weeks will be the primary outcome; all other endpoints will be secondary.Safety will be assessed by performing blood tests and electrocardiograms before taking the investigational drug, 6 weeks after taking the drug, and 12 weeks after taking the drug; any adverse events will be observed throughout the study.DiscussionThe protocol will provide a detailed process for a clinical trial to evaluate the efficacy and safety of KGT in elderly patients with insomnia. We will also investigate if changes in cognitive function correlated with improvements in insomnia.Trial registrationThis trial was registered at CRIS (Clinical Research Information Service) on April 27, 2023 (KCT0008391, version 2.0). https://cris.nih.go.kr/cris/search/detailSearch.do?seq=24811&search_page=L.
BACKGROUND: The incidence of insomnia increases with age and is related to cognitive function in older adults; therefore, it is important to manage it actively. In this study, we report a protocol for the evaluation of the efficacy and safety of Kami Guibi-tang (KGT), a herbal prescription that has been widely used in East Asia for insomnia, forgetfulness, and depression, in older adults with insomnia. METHODS: In this single-center, double-blind, randomized controlled trial, 60 older adults with insomnia and subjective cognitive decline will be recruited and randomly assigned to the KGT or placebo group. The KGT group will take KGT granules thrice a day for 12 weeks, whereas the control group will take placebo granules in the same manner. Participants will be assessed for sleep, cognitive function, quality of life, and depression using the Pittsburgh Sleep Quality Index-Korean (PSQI-K), Insomnia Severity Index-Korean (ISI-K), Seoul Neuropsychological Screening Battery–Dement (SNSB-D), 36-item MOS Short Form Survey (SF-36) and Short version of the Geriatric Depression Scale (S-GDS) before and at the end of administration of the investigational product. The PSQI-K, ISI-K, and SF-36 will be further assessed 12 weeks after the end of medication to determine whether the effects on sleep and quality of life are sustained. The PSQI-K total score difference between the two groups at 12 and 24 weeks will be the primary outcome; all other endpoints will be secondary. Safety will be assessed by performing blood tests and electrocardiograms before taking the investigational drug, 6 weeks after taking the drug, and 12 weeks after taking the drug; any adverse events will be observed throughout the study. DISCUSSION: The protocol will provide a detailed process for a clinical trial to evaluate the efficacy and safety of KGT in elderly patients with insomnia. We will also investigate if changes in cognitive function correlated with improvements in insomnia. TRIAL REGISTRATION: This trial was registered at CRIS (Clinical Research Information Service) on April 27, 2023 (KCT0008391, version 2.0). https://cris.nih.go.kr/cris/search/detailSearch.do?seq=24811&search_page=L .
Abstract Background The incidence of insomnia increases with age and is related to cognitive function in older adults; therefore, it is important to manage it actively. In this study, we report a protocol for the evaluation of the efficacy and safety of Kami Guibi-tang (KGT), a herbal prescription that has been widely used in East Asia for insomnia, forgetfulness, and depression, in older adults with insomnia. Methods In this single-center, double-blind, randomized controlled trial, 60 older adults with insomnia and subjective cognitive decline will be recruited and randomly assigned to the KGT or placebo group. The KGT group will take KGT granules thrice a day for 12 weeks, whereas the control group will take placebo granules in the same manner. Participants will be assessed for sleep, cognitive function, quality of life, and depression using the Pittsburgh Sleep Quality Index-Korean (PSQI-K), Insomnia Severity Index-Korean (ISI-K), Seoul Neuropsychological Screening Battery–Dement (SNSB-D), 36-item MOS Short Form Survey (SF-36) and Short version of the Geriatric Depression Scale (S-GDS) before and at the end of administration of the investigational product. The PSQI-K, ISI-K, and SF-36 will be further assessed 12 weeks after the end of medication to determine whether the effects on sleep and quality of life are sustained. The PSQI-K total score difference between the two groups at 12 and 24 weeks will be the primary outcome; all other endpoints will be secondary. Safety will be assessed by performing blood tests and electrocardiograms before taking the investigational drug, 6 weeks after taking the drug, and 12 weeks after taking the drug; any adverse events will be observed throughout the study. Discussion The protocol will provide a detailed process for a clinical trial to evaluate the efficacy and safety of KGT in elderly patients with insomnia. We will also investigate if changes in cognitive function correlated with improvements in insomnia. Trial registration This trial was registered at CRIS (Clinical Research Information Service) on April 27, 2023 (KCT0008391, version 2.0).  https://cris.nih.go.kr/cris/search/detailSearch.do?seq=24811&search_page=L .
ArticleNumber 375
Audience Academic
Author Moon, Sang-Kwan
Park, Jung-Mi
Ko, Chang-Nam
Lee, Kyeong-Hwa
Lee, Han-Gyul
Park, Seong-Uk
Cho, Seung-Yeon
Jung, Woo-Sang
Kwon, Seungwon
Author_xml – sequence: 1
  givenname: Kyeong-Hwa
  surname: Lee
  fullname: Lee, Kyeong-Hwa
– sequence: 2
  givenname: Han-Gyul
  surname: Lee
  fullname: Lee, Han-Gyul
– sequence: 3
  givenname: Seungwon
  surname: Kwon
  fullname: Kwon, Seungwon
– sequence: 4
  givenname: Seong-Uk
  surname: Park
  fullname: Park, Seong-Uk
– sequence: 5
  givenname: Woo-Sang
  surname: Jung
  fullname: Jung, Woo-Sang
– sequence: 6
  givenname: Sang-Kwan
  surname: Moon
  fullname: Moon, Sang-Kwan
– sequence: 7
  givenname: Jung-Mi
  surname: Park
  fullname: Park, Jung-Mi
– sequence: 8
  givenname: Chang-Nam
  surname: Ko
  fullname: Ko, Chang-Nam
– sequence: 9
  givenname: Seung-Yeon
  surname: Cho
  fullname: Cho, Seung-Yeon
BookMark eNqFkt1qFDEUxwep2Fr7Al4FBKnQqclkksx4I6XUWix4U69DJnOymyWTrElGWZ_FhzXbLdoVQRJIcs7v_Mn5eF4d-OChql4SfE5Ix98m0vSY17ihNW5J39ebJ9VRw3lTCy7IwaP7YXWS0grjghIqKHtWHVLRiYZhflT9vDIGdEbBoE9qsuh6toOts_ILdPrp-u4Nsh6BGyG6DUrzsCpsQt9tXhZHCpO36h1SKOV53KB1DDno4JCJYdparV84QBp8hniGovJjmOwPGM_QGObBQT0468tr7ZSGIdQ6-ByDczCiHK1yL6qnRrkEJw_ncfXlw9Xd5cf69vP1zeXFba0Z47luG1B4NILwQRg6aMWNAGCgVCOU6RgxQHGnMDX90OqmZ10rhk4TpZUeGAN6XN3sdMegVnId7aTiRgZl5b0hxIVUMVvtQILRRAg1cGpMq_XQ8Z72YEzfihEEV0Xr_U5rPQ8TjNvko3J7ovseb5dyEb5JglnfdqQvCqcPCjF8nSFlOdmkwTnlIcxJUsJo6S0t-39o03WkaQURW9VXf6GrMEdfylqoHmMmmGj_UAtVkrXehPJHvRWVF0Jg3Jc8eaHO_0GVNcJkSxPB2GLfC3j9KGAJyuVlCm7ONvi0DzY7UMeQUgTzu3AEy-3cy93cyzLM8n7u5Yb-AmFP9qc
Cites_doi 10.1254/jjp.54.375
10.3389/fpsyt.2017.00132
10.1155/2018/9475919
10.1016/0022-3956(82)90033-4
10.1176/appi.books.9780890425596
10.3390/ijerph17134862
10.1186/1472-6882-8-49
10.1016/S1389-9457(00)00065-4
10.1007/s40266-018-0569-8
10.7326/M15-1781
10.1016/0165-1781(89)90047-4
10.3346/jkms.2010.25.7.1071
10.5665/sleep.4172
10.1016/j.smrv.2011.03.008
10.1016/j.smrv.2019.07.008
10.1212/WNL.34.7.939
10.1007/s00038-015-0682-y
10.1093/sleep/32.4.491
10.4306/jknpa.2020.59.1.2
10.1016/j.jalz.2011.03.008
10.4097/kjae.2017.70.2.144
10.1093/gerona/55.7.M406
10.1007/s11325-011-0579-9
10.5664/jcsm.26929
10.21203/rs.3.rs-2345089/v1
10.12779/dnd.2023.22.1.1
10.1097/00005650-199206000-00002
10.1254/jjp.64.171
10.3109/00207454.2011.602809
10.1016/j.amjmed.2005.10.051
10.1046/j.1532-5415.2001.49235.x
10.30773/pi.2019.0218
10.1155/2023/4846770
10.1111/j.1447-0594.2007.00407.x
10.3988/jcn.2014.10.3.210
10.1161/HYPERTENSIONAHA.112.193268
10.1016/j.jpsychires.2012.07.001
10.5665/sleep.3836
10.1111/jgs.13702
10.1111/j.1365-2869.2010.00863.x
10.1016/j.pop.2005.03.001
10.1016/j.jpsychores.2004.01.004
10.1177/1534735417734914
10.1093/sleep/33.4.459
10.1016/j.smrv.2011.12.005
10.1016/j.smrv.2017.06.010
10.1186/s12906-021-03428-6
ContentType Journal Article
Copyright COPYRIGHT 2023 BioMed Central Ltd.
2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
2023. BioMed Central Ltd., part of Springer Nature.
BioMed Central Ltd., part of Springer Nature 2023
Copyright_xml – notice: COPYRIGHT 2023 BioMed Central Ltd.
– notice: 2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: 2023. BioMed Central Ltd., part of Springer Nature.
– notice: BioMed Central Ltd., part of Springer Nature 2023
DBID AAYXX
CITATION
3V.
7TK
7U7
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AEUYN
AFKRA
AZQEC
BENPR
C1K
CCPQU
DWQXO
FYUFA
GHDGH
K9.
M0S
M1P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
7X8
7S9
L.6
5PM
DOA
DOI 10.1186/s12906-023-04199-y
DatabaseName CrossRef
ProQuest Central (Corporate)
Neurosciences Abstracts
Toxicology Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest One Sustainability
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
Environmental Sciences and Pollution Management
ProQuest One Community College
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
Health & Medical Collection (Alumni)
Proquest Medical Database
ProQuest Central Premium
ProQuest One Academic
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
MEDLINE - Academic
AGRICOLA
AGRICOLA - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
Environmental Sciences and Pollution Management
ProQuest Central
ProQuest One Sustainability
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
Toxicology Abstracts
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Neurosciences Abstracts
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
AGRICOLA
AGRICOLA - Academic
DatabaseTitleList


MEDLINE - Academic
Publicly Available Content Database
AGRICOLA
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2662-7671
1472-6882
EndPage 375
ExternalDocumentID oai_doaj_org_article_efc177ab63ff4ccb86939eff947de76a
PMC10594819
A770099476
10_1186_s12906_023_04199_y
GeographicLocations South Korea
East Asia
GeographicLocations_xml – name: South Korea
– name: East Asia
GroupedDBID 53G
7X7
88E
8FI
8FJ
AAFWJ
AAJSJ
AASML
AAYXX
ABUWG
ADUKV
AEUYN
AFKRA
AFPKN
ALMA_UNASSIGNED_HOLDINGS
BENPR
BMC
C6C
CCPQU
CITATION
EBLON
EBS
EMB
EMOBN
FYUFA
GROUPED_DOAJ
HMCUK
IAO
IHR
IHW
INH
ITC
M1P
M~E
PGMZT
PHGZM
PHGZT
PIMPY
PSQYO
ROL
RPM
RSV
SOJ
SV3
UKHRP
PMFND
---
0R~
23N
2WC
3V.
5VS
6J9
6PF
7TK
7U7
7XB
8FK
A8Z
AAHBH
AAWTL
ACGFO
ACGFS
ACMJI
ACPRK
ADBBV
ADRAZ
AENEX
AFRAH
AHBYD
AHMBA
AHYZX
ALIPV
AMKLP
AOIJS
AZQEC
BAWUL
BCNDV
BFQNJ
BPHCQ
BVXVI
C1K
CS3
DIK
DU5
DWQXO
E3Z
F5P
GX1
HYE
INR
K9.
KQ8
O5R
O5S
OVT
P2P
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PROAC
RBZ
RNS
SMD
TR2
UNMZH
W2D
WOQ
WOW
XSB
7X8
7S9
L.6
5PM
PUEGO
ID FETCH-LOGICAL-c556t-42ea0df716b7f3bca6f7ee5eaa27af851fe308a03f9b4c295847b8c1acacb55e3
IEDL.DBID 7X7
ISSN 2662-7671
IngestDate Wed Aug 27 01:29:55 EDT 2025
Thu Aug 21 18:35:51 EDT 2025
Fri Jul 11 15:34:28 EDT 2025
Mon Jul 21 11:01:28 EDT 2025
Mon Jun 30 15:46:24 EDT 2025
Tue Jun 17 22:20:11 EDT 2025
Tue Jun 10 21:24:15 EDT 2025
Thu May 22 21:13:50 EDT 2025
Tue Jul 01 03:51:53 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
License Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c556t-42ea0df716b7f3bca6f7ee5eaa27af851fe308a03f9b4c295847b8c1acacb55e3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Article-2
ObjectType-Undefined-1
ObjectType-Feature-3
content type line 23
OpenAccessLink https://www.proquest.com/docview/2890057574?pq-origsite=%requestingapplication%
PMID 37872506
PQID 2890057574
PQPubID 44230
PageCount 1
ParticipantIDs doaj_primary_oai_doaj_org_article_efc177ab63ff4ccb86939eff947de76a
pubmedcentral_primary_oai_pubmedcentral_nih_gov_10594819
proquest_miscellaneous_3153662362
proquest_miscellaneous_2881247179
proquest_journals_2890057574
gale_infotracmisc_A770099476
gale_infotracacademiconefile_A770099476
gale_healthsolutions_A770099476
crossref_primary_10_1186_s12906_023_04199_y
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2023-10-23
PublicationDateYYYYMMDD 2023-10-23
PublicationDate_xml – month: 10
  year: 2023
  text: 2023-10-23
  day: 23
PublicationDecade 2020
PublicationPlace London
PublicationPlace_xml – name: London
PublicationTitle BMC complementary and alternative medicine
PublicationYear 2023
Publisher BioMed Central Ltd
BioMed Central
BMC
Publisher_xml – name: BioMed Central Ltd
– name: BioMed Central
– name: BMC
References AY Avidan (4199_CR39) 2005; 32
A Yoshimura (4199_CR17) 2018; 2018
HR Kim (4199_CR20) 2023; 2023
MS Albert (4199_CR30) 2011; 7
JY Lee (4199_CR18) 2018; 17
S Chung (4199_CR37) 2020; 17
SJ Kim (4199_CR9) 2020; 59
SI Sohn (4199_CR24) 2012; 16
E Fortier-Brochu (4199_CR23) 2014; 37
VC Abad (4199_CR14) 2018; 35
G McKhann (4199_CR29) 1984; 34
SG Kwak (4199_CR35) 2017; 70
4199_CR1
L Shi (4199_CR43) 2018; 40
V van de Straat (4199_CR3) 2015; 60
É Fortier-Brochu (4199_CR48) 2012; 16
4199_CR40
EY Joo (4199_CR49) 2014; 37
NS Kamel (4199_CR7) 2006; 119
YW Cho (4199_CR33) 2014; 10
Y Leng (4199_CR13) 2022; Preprint
K Nishizawa (4199_CR44) 1994; 64
S Wardle-Pinkston (4199_CR47) 2019; 48
M Cricco (4199_CR12) 2001; 49
HJ Ahn (4199_CR25) 2010; 25
D Song (4199_CR42) 2020; 17
C Tohda (4199_CR22) 2011; 121
J Fernandez-Mendoza (4199_CR4) 2012; 60
HY Shin (4199_CR19) 2021; 21
HJ Ryu (4199_CR26) 2023; 22
CH Bastien (4199_CR32) 2001; 2
T Roth (4199_CR36) 2007; 3
C Tohda (4199_CR21) 2008; 8
JA Yesavage (4199_CR34) 1982; 17
4199_CR38
K Higashi (4199_CR46) 2007; 7
K Spiegelhalder (4199_CR5) 2011; 20
WF Yeung (4199_CR15) 2012; 16
SI Babar (4199_CR41) 2000; 55
AN Vgontzas (4199_CR6) 2009; 32
JN Bae (4199_CR28) 2004; 57
DJ Buysse (4199_CR31) 1989; 28
TJ Wilt (4199_CR10) 2016; 165
J Fernandez-Mendoza (4199_CR8) 2010; 33
American Geriatrics Society (4199_CR11) 2015; 63
K Ito (4199_CR16) 2017; 8
4199_CR27
K Nishizawa (4199_CR45) 1990; 54
JG Ellis (4199_CR2) 2012; 46
References_xml – volume: 54
  start-page: 375
  issue: 4
  year: 1990
  ident: 4199_CR45
  publication-title: Jpn J Pharmacol
  doi: 10.1254/jjp.54.375
– volume: 8
  start-page: 132
  year: 2017
  ident: 4199_CR16
  publication-title: Front Psychiatry
  doi: 10.3389/fpsyt.2017.00132
– volume: 2018
  start-page: 9475919
  year: 2018
  ident: 4199_CR17
  publication-title: Obstet Gynecol Int
  doi: 10.1155/2018/9475919
– volume: 17
  start-page: 37
  issue: 1
  year: 1982
  ident: 4199_CR34
  publication-title: J Psychiatr Res
  doi: 10.1016/0022-3956(82)90033-4
– ident: 4199_CR1
  doi: 10.1176/appi.books.9780890425596
– volume: 17
  start-page: 4862
  issue: 13
  year: 2020
  ident: 4199_CR42
  publication-title: Int J Environ Res Public Health
  doi: 10.3390/ijerph17134862
– volume: 8
  start-page: 49
  year: 2008
  ident: 4199_CR21
  publication-title: BMC Complement Altern Med
  doi: 10.1186/1472-6882-8-49
– volume: 2
  start-page: 297
  issue: 4
  year: 2001
  ident: 4199_CR32
  publication-title: Sleep Med
  doi: 10.1016/S1389-9457(00)00065-4
– volume: 35
  start-page: 791
  year: 2018
  ident: 4199_CR14
  publication-title: Drugs Aging
  doi: 10.1007/s40266-018-0569-8
– volume: 165
  start-page: 103
  issue: 2
  year: 2016
  ident: 4199_CR10
  publication-title: Ann Intern Med
  doi: 10.7326/M15-1781
– volume: 28
  start-page: 193
  issue: 2
  year: 1989
  ident: 4199_CR31
  publication-title: Psychiatry Res
  doi: 10.1016/0165-1781(89)90047-4
– volume: 25
  start-page: 1071
  issue: 7
  year: 2010
  ident: 4199_CR25
  publication-title: J Korean Med Sci
  doi: 10.3346/jkms.2010.25.7.1071
– volume: 37
  start-page: 1787
  issue: 11
  year: 2014
  ident: 4199_CR23
  publication-title: Sleep
  doi: 10.5665/sleep.4172
– volume: 16
  start-page: 83
  issue: 1
  year: 2012
  ident: 4199_CR48
  publication-title: Sleep Med Rev
  doi: 10.1016/j.smrv.2011.03.008
– volume: 48
  start-page: 101205
  year: 2019
  ident: 4199_CR47
  publication-title: Sleep Med Rev
  doi: 10.1016/j.smrv.2019.07.008
– volume: 34
  start-page: 939
  issue: 7
  year: 1984
  ident: 4199_CR29
  publication-title: Neurology
  doi: 10.1212/WNL.34.7.939
– volume: 60
  start-page: 643
  year: 2015
  ident: 4199_CR3
  publication-title: Int J Public Health
  doi: 10.1007/s00038-015-0682-y
– volume: 32
  start-page: 491
  issue: 4
  year: 2009
  ident: 4199_CR6
  publication-title: Sleep
  doi: 10.1093/sleep/32.4.491
– volume: 59
  start-page: 2
  issue: 1
  year: 2020
  ident: 4199_CR9
  publication-title: J Korean Neuropsychiatric Association
  doi: 10.4306/jknpa.2020.59.1.2
– volume: 7
  start-page: 270
  issue: 3
  year: 2011
  ident: 4199_CR30
  publication-title: Alzheimer’s Dement
  doi: 10.1016/j.jalz.2011.03.008
– volume: 70
  start-page: 144
  issue: 2
  year: 2017
  ident: 4199_CR35
  publication-title: Korean J Anesthesiol
  doi: 10.4097/kjae.2017.70.2.144
– volume: 55
  start-page: M406
  issue: 7
  year: 2000
  ident: 4199_CR41
  publication-title: The Journals of Gerontology Series A: Biological Sciences and Medical Sciences
  doi: 10.1093/gerona/55.7.M406
– volume: 16
  start-page: 803
  issue: 3
  year: 2012
  ident: 4199_CR24
  publication-title: Sleep Breath
  doi: 10.1007/s11325-011-0579-9
– volume: Preprint
  start-page: 1
  year: 2022
  ident: 4199_CR13
  publication-title: J Alzheimers Dis
– volume: 3
  start-page: 7
  issue: 5 suppl
  year: 2007
  ident: 4199_CR36
  publication-title: J Clin Sleep Med
  doi: 10.5664/jcsm.26929
– ident: 4199_CR40
  doi: 10.21203/rs.3.rs-2345089/v1
– volume: 22
  start-page: 1
  issue: 1
  year: 2023
  ident: 4199_CR26
  publication-title: Dement Neurocogn Disord
  doi: 10.12779/dnd.2023.22.1.1
– ident: 4199_CR27
  doi: 10.1097/00005650-199206000-00002
– volume: 64
  start-page: 171
  issue: 3
  year: 1994
  ident: 4199_CR44
  publication-title: Jpn J Pharmacol
  doi: 10.1254/jjp.64.171
– volume: 121
  start-page: 641
  issue: 12
  year: 2011
  ident: 4199_CR22
  publication-title: Int J Neurosci
  doi: 10.3109/00207454.2011.602809
– volume: 119
  start-page: 463
  issue: 6
  year: 2006
  ident: 4199_CR7
  publication-title: Am J Med
  doi: 10.1016/j.amjmed.2005.10.051
– volume: 49
  start-page: 1185
  issue: 9
  year: 2001
  ident: 4199_CR12
  publication-title: J Am Geriatr Soc
  doi: 10.1046/j.1532-5415.2001.49235.x
– volume: 17
  start-page: 533
  issue: 6
  year: 2020
  ident: 4199_CR37
  publication-title: Psychiatry Invest
  doi: 10.30773/pi.2019.0218
– volume: 2023
  start-page: 4846770
  year: 2023
  ident: 4199_CR20
  publication-title: Evid Based Complement Alternat Med
  doi: 10.1155/2023/4846770
– volume: 7
  start-page: 245
  issue: 3
  year: 2007
  ident: 4199_CR46
  publication-title: Geriatr Gerontol Int
  doi: 10.1111/j.1447-0594.2007.00407.x
– volume: 10
  start-page: 210
  issue: 3
  year: 2014
  ident: 4199_CR33
  publication-title: J Clin Neurol
  doi: 10.3988/jcn.2014.10.3.210
– volume: 60
  start-page: 929
  issue: 4
  year: 2012
  ident: 4199_CR4
  publication-title: Hypertension
  doi: 10.1161/HYPERTENSIONAHA.112.193268
– volume: 46
  start-page: 1278
  issue: 10
  year: 2012
  ident: 4199_CR2
  publication-title: J Psychiatr Res
  doi: 10.1016/j.jpsychires.2012.07.001
– volume: 37
  start-page: 1189
  issue: 7
  year: 2014
  ident: 4199_CR49
  publication-title: Sleep
  doi: 10.5665/sleep.3836
– volume: 63
  start-page: 2227
  issue: 11
  year: 2015
  ident: 4199_CR11
  publication-title: J Am Geriatr Soc
  doi: 10.1111/jgs.13702
– ident: 4199_CR38
– volume: 20
  start-page: 137
  issue: 1pt2
  year: 2011
  ident: 4199_CR5
  publication-title: J Sleep Res
  doi: 10.1111/j.1365-2869.2010.00863.x
– volume: 32
  start-page: 563
  issue: 2
  year: 2005
  ident: 4199_CR39
  publication-title: Prim Care: Clin Office Pract
  doi: 10.1016/j.pop.2005.03.001
– volume: 57
  start-page: 297
  issue: 3
  year: 2004
  ident: 4199_CR28
  publication-title: J Psychosom Res
  doi: 10.1016/j.jpsychores.2004.01.004
– volume: 17
  start-page: 524
  issue: 2
  year: 2018
  ident: 4199_CR18
  publication-title: Integr Cancer Ther
  doi: 10.1177/1534735417734914
– volume: 33
  start-page: 459
  issue: 4
  year: 2010
  ident: 4199_CR8
  publication-title: Sleep
  doi: 10.1093/sleep/33.4.459
– volume: 16
  start-page: 497
  issue: 6
  year: 2012
  ident: 4199_CR15
  publication-title: Sleep Med Rev
  doi: 10.1016/j.smrv.2011.12.005
– volume: 40
  start-page: 4
  year: 2018
  ident: 4199_CR43
  publication-title: Sleep Med Rev
  doi: 10.1016/j.smrv.2017.06.010
– volume: 21
  start-page: 251
  issue: 1
  year: 2021
  ident: 4199_CR19
  publication-title: BMC Complement Med Ther
  doi: 10.1186/s12906-021-03428-6
SSID ssj0002313735
ssj0017814
Score 2.2360706
Snippet Background The incidence of insomnia increases with age and is related to cognitive function in older adults; therefore, it is important to manage it actively....
The incidence of insomnia increases with age and is related to cognitive function in older adults; therefore, it is important to manage it actively. In this...
BackgroundThe incidence of insomnia increases with age and is related to cognitive function in older adults; therefore, it is important to manage it actively....
BACKGROUND: The incidence of insomnia increases with age and is related to cognitive function in older adults; therefore, it is important to manage it...
Abstract Background The incidence of insomnia increases with age and is related to cognitive function in older adults; therefore, it is important to manage it...
SourceID doaj
pubmedcentral
proquest
gale
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
StartPage 375
SubjectTerms Adults
Aged patients
biomedical research
Blood
Bulletin boards
Cardiovascular disease
Clinical medicine
Clinical trials
cognition
Cognition & reasoning
Cognitive ability
cognitive disorders
complement
Consent
Dementia
Depression, Mental
drug therapy
Drugs
East Asia
Effectiveness
elderly
Electrocardiogram
Electrocardiography
Geriatrics
Granular materials
Herbal medicine
Hospitals
Insomnia
Kami Guibi-tang
Medical examination
Medical research
Medicine, Experimental
Mental disorders
Neuropsychology
Older people
Patients
Placebos
Protocol
Psychotropic drugs
Quality of life
Questionnaires
Randomized controlled trial
Safety
Sleep
Sleep deprivation
Sleep disorders
Study Protocol
Subjective cognitive decline
surveys
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQD4gL4ikCBYyEBIhaTeLEjrkVRFtRlVMr9Wb5CUG7CeruHpbfwo9lxsmuNiDEhWPiiZR4ZjKfPTOfCXnp8op7n-esiTlnmBhiVpiSeV7wwqvG14m78_yzOL2sPl3VVztHfWFN2EAPPEzcYYiukNJYwWOsnLONUFyFGFUlfZAiQSOIeTuLqW-JxKXgktebLplGHC5wwwXrbTnLq0Iptp5EokTY_-dv-fdSyZ3Yc3yH3B5BIz0aXvYuuRG6e-Tm-ZgWv09-DhzEtI_0zMxberJqbcsA9n2hr89OLt7QtqMBj-OereliZXHrZUFxB5Zi79e8a807amhimqVI3NCDdVBsPMG7ENtmgeKbhesDCqHN9_P2R_AH1PcrOwvMAlKFq1TdZXs2Fr_PgqfpSJAH5PL448WHUzYeu8BcXYslq8pgch9hIWVl5NYZEWUIdTCmlCYCQouB543JeVS2cqXCRKttXGGccbauA39I9rq-C48IBd0JHwXEYcwm5rFRso4lsr65RhTeZuTtRgX6-8CuodOqpBF6UJgGhemkML3OyHvU0lYSmbHTDbAXPdqL_pe9ZOQ56lgPbaZb_9ZHUiJarqTIyKskgR4OOoevGhoV4JOQK2siuT-RBM900-GNHenxz7DQmNhFjCyrjLzYDuOTWO3WhX6FMgi7YKGt_i7DIVQJwK6izEgzsdHJ_ExHuvZrYhAvBpYe9fh_zOgTcqtEt4KAXvJ9sre8XoWngNSW9llyyl8uHD-9
  priority: 102
  providerName: Directory of Open Access Journals
Title Effect of Kami Guibi-tang (KGT) in elderly subjects with insomnia: a study protocol from a single center, randomized, double-blind, placebo-controlled trial
URI https://www.proquest.com/docview/2890057574
https://www.proquest.com/docview/2881247179
https://www.proquest.com/docview/3153662362
https://pubmed.ncbi.nlm.nih.gov/PMC10594819
https://doaj.org/article/efc177ab63ff4ccb86939eff947de76a
Volume 23
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1ba9RAFB60BfFFvGK0riMIKnZokklmEl-kK71gaZHSwuLLMNc2sJvU3c3D-lv8sc6ZZFej6EsgmRNyOXPmnDmX7yD0WscZNSaOSeFiSiAwRBSTKTE0oYkpC5MH7M7TM3Z8mX2e5JPe4bbo0yrXa2JYqE2jwUe-BwExsC149vHmG4GuURBd7Vto3EbbAF0GKV18stlwJQDntC6UKdjeAnwukHJLSZwlZUlWA2UUMPv_Xpn_zJb8Tf0c3kf3ersR73eMfoBu2fohunPaR8YfoR8dDDFuHD6RswoftZWqiLf8rvDbk6OLd7iqsYWO3NMVXrQKvC8LDE5YDOVfs7qSH7DEAWwWA3ZD4ycIhtoTuOrV29RieDM738Veu5lmVn23ZhebplVTS5Q3Vv1ZSPBSDenz36fW4NAV5DG6PDy4-HRM-s4LROc5W5IstTI2zu-lFHdUackctza3UqZcOm-kOUvjQsbUlSrTaQmxVlXoRGqpVZ5b-gRt1U1tnyLsdMKMY14VQ0AxdkXJc5cC8JsuWGJUhN6vWSBuOoANETYmBRMdw4RnmAgME6sIjYFLG0oAxw4XmvmV6GVNWP9MzqVi1LlMa1WwkpbWuTLjxnImI_QSeCy6StONiIt9zsFgzjiL0JtAAULuee6_qqtV8J8EcFkDyp0BpRdOPRxezyPRLw4L8WsqR-jVZhjuhIS32jYt0IDl5ffa5b9pqNdWzJuvLI1QMZijg_8zHKmr6wAinnRAPeWz_7_hc3Q3BYHx2jqlO2hrOW_tC2-GLdUoyNoIbY8Pzr6cj4Izwx_Px19HwWf2E5SHOY4
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Zb9NAEF6VVAJeEKdqKHSRQIDoqrbXXttICLXQNiVNhVAq9W3Zs1hK7JJDKPwWfgO_kR0fAYPgrY_xThLbMzvHzsw3CD1RfkS19n2SWp8SSAwRyURINA1ooLNUxxV25_CE9U-j92fx2Rr60fbCQFllqxMrRa1LBWfkO5AQA98iid5cfCEwNQqyq-0IjVosBmb51YVss9dH7xx_n4bhwf7obZ80UwWIimM2J1FohK-tixNkYqlUgtnEmNgIESbCOgfEGuqnwqc2k5EKM8gjylQFQgkl49hQ97tX0HpEXSjTQ-t7-ycfPq7yFgAg1bbmpGxnBqc8UORLiR8FWUaWHfNXTQn42xb8WZ_5m8E7uIluNJ4q3q1F6xZaM8VtdHXY5OLvoO818DEuLR6ISY4PF7nMifM1z_HzweHoBc4LbGAG-HiJZwsJ5z0zDMe-GBrOJkUuXmGBK3hbDGgRpRNJDN0ucNUZ1LHBcGdmuo2dPdXlJP9m9DbW5UKODZHOPXafqpIyWZKm4n5sNK7mkNxFp5fClXuoV5SF2UDYqoBpy5zxhxSmb9MsiW0IUHMqZYGWHnrZsoBf1JAevAqFUsZrhnHHMF4xjC89tAdcWlECHHd1oZye82Z3c-P-M0mEZNTaSCmZsoxmxtosSrRJmPDQFvCY172tK6XCd5MEXPQoYR56VlGAWnE8d09Vd0e4RwKArg7lZofSqQPVXW7liDfqaMZ_bR4PPV4twzehxK4w5QJowNdz0X32bxrq7CNzDjMLPZR2ZLTzfrorRf65gi0Pamig7P7_73ALXeuPhsf8-Ohk8ABdD2HzOF8hpJuoN58uzEPnBM7lo2bnYfTpsjf7TzDudYE
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Effect+of+Kami+Guibi-tang+in+elderly+subjects+with+insomnia%3A+a+study+protocol+from+a+single+center%2C+randomized%2C+double-blind%2C+placebo-controlled+trial&rft.jtitle=BMC+complementary+medicine+and+therapies&rft.au=Lee%2C+Kyeong-Hwa&rft.au=Lee%2C+Han-Gyul&rft.au=Kwon%2C+Seungwon&rft.au=Park%2C+Seong-Uk&rft.date=2023-10-23&rft.pub=BioMed+Central+Ltd&rft.issn=2662-7671&rft.eissn=2662-7671&rft.volume=23&rft.issue=1&rft_id=info:doi/10.1186%2Fs12906-023-04199-y&rft.externalDocID=A770099476
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2662-7671&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2662-7671&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2662-7671&client=summon